Iba Press Release - HY 2020 RESULTS – AMENDMENT TO TIMING OF PUBLICATION

HY 2020 Results – amendment to timing of publication

Louvain-La-Neuve, Belgium, 26 August 2020 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, IBA announces that, ahead of reporting its half year 2020 financial results today, there is an amendment to the timing of the publication. The Group will now publish its results today at 10am CEST. IBA shares will be suspended from trading until the publication of the announcement.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

For further information, please contact:

IBA

Soumya Chandramouli

Chief Financial Officer

Thomas Ralet

Head of Corporate Communication

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone, Lizzie Seeley

+44 (0) 20 3709 5700

Attachments